We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Snibe Showcases Maglumi X3 Fully Automatic CLIA System at EUROMEDLAB 2022

By LabMedica International staff writers
Posted on 12 Apr 2022
Print article
Image: Maglumi X3 fully automatic CLIA system (Photo courtesy of Snibe)
Image: Maglumi X3 fully automatic CLIA system (Photo courtesy of Snibe)

Snibe (Shenzhen, China) showcased its new fully automatic Chemiluminescence Immunoassay (CLIA) system at the 24th IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine, EUROMEDLAB 2022, in Munich, Germany. EUROMEDLAB is the most influential platform in Europe where new ideas and technologies in laboratory diagnostics are shared and showcased.

At EUROMEDLAB 2022, Snibe demonstrated its new Maglumi X3 fully automatic CLIA system that is small but powerful, with a throughput of up to 200 tests per hour and a throughput per unit area is 294 tests per hour/m². One of the highest space efficiency CLIA analyzers, the Maglumi X3 combines one of the broadest automated CLIA test menus (181 parameters) and is compatible with all Maglumi reagents.

Its single reaction cup can avoid light pollution and increase cuvette utilization, while its integrated packaging can prevent the cuvette from sticking and destroying the cuvette wall. The MAGLUMI X3 features pipetting detection technologies such as liquid level, clot, and crash detection to ensure accurate and normal pipetting. It features the latest intelligent washing technology and bidirectional temperature control measurement to guarantee accurate and reliable results. With its advanced design, intelligent UI interface, user-friendly, easy, and convenient operation, the MAGLUMI X3 ensures excellent performance and is ideal for small and medium-sized hospitals and laboratories.

Related Links:
Snibe 

Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
New
Gold Member
Veterinary Hematology Analyzer
Exigo H400
New
DVT/PE Test
VIDAS D-DIMER EXCLUSION II
New
Rheumatoid Arthritis Test
Finecare RF Rapid Quantitative Test

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.